Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025129 · ClinicalTrials.gov registry record · Phase 1
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
A Phase 1 study, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00025129: Completed Phase 1 study, sponsored by Vion Pharmaceuticals.
NCT00025129 is a Phase 1 study that has completed, run by Vion Pharmaceuticals. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025129, a Phase 1 study, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced solid tumors or lymphomas.
Interventions
- DRUG laromustine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-03 |
| Est. Completion | 2004-05 |
| Phase | Phase 1 |
What the finished NCT00025129 record still lists
NCT00025129 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which laromustine is the first listed.
NCT00025129 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00025129 about?
NCT00025129 is a clinical study titled "VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced solid tumors or lymphomas.
What is the current status of trial NCT00025129?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-03. Estimated completion is 2004-05.
What interventions are being tested in trial NCT00025129?
The interventions under investigation include: laromustine (DRUG).
Who is sponsoring clinical trial NCT00025129?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia